z-logo
open-access-imgOpen Access
Microtubule-Driven Stress Granule Dynamics Regulate Inhibitory Immune Checkpoint Expression in T Cells
Author(s) -
DonMarc Franchini,
Olivia Lanvin,
Marie Tosolini,
Emilie Patras de Campaigno,
Anne Cammas,
Sarah Péricart,
ClaraMaria Scarlata,
Morgane Le Bras,
Cédric Rossi,
Lætitia Ligat,
Frédéric Pont,
Paola B. Arimondo,
Camille Laurent,
Maha Ayyoub,
Fabien Despas,
Maryse LapeyreMestre,
Stefania Millevoi,
JeanJacques Fournié
Publication year - 2019
Publication title -
cell reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.264
H-Index - 154
eISSN - 2639-1856
pISSN - 2211-1247
DOI - 10.1016/j.celrep.2018.12.014
Subject(s) - btla , tigit , microbiology and biotechnology , immune system , stress granule , microtubule , biology , immune checkpoint , inhibitory postsynaptic potential , receptor , cancer research , t cell , translation (biology) , immunotherapy , immunology , neuroscience , messenger rna , genetics , gene
Despite the clinical success of blocking inhibitory immune checkpoint receptors such as programmed cell death-1 (PD-1) in cancer, the mechanisms controlling the expression of these receptors have not been fully elucidated. Here, we identify a post-transcriptional mechanism regulating PD-1 expression in T cells. Upon activation, the PDCD1 mRNA and ribonucleoprotein complexes coalesce into stress granules that require microtubules and the kinesin 1 molecular motor to proceed to translation. Hence, PD-1 expression is highly sensitive to microtubule or stress granule inhibitors targeting this pathway. Evidence from healthy donors and cancer patients reveals a common regulation for the translation of CTLA4, LAG3, TIM3, TIGIT, and BTLA but not of the stimulatory co-receptors OX40, GITR, and 4-1BB mRNAs. In patients, disproportionality analysis of immune-related adverse events for currently used microtubule drugs unveils a significantly higher risk of autoimmunity. Our findings reveal a fundamental mechanism of immunoregulation with great importance in cancer immunotherapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom